Rainmed Medical Limited (HK:2297)
:2297
Want to see HK:2297 full AI Analyst Report?
2297 Stock Chart & Stats
HK$0.26
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.26
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$0.53
Previous CloseN/A
Volume40.00K
Average Volume (3M)3.71M
Market Cap
HK$371.36M
Enterprise ValueHK$280.35M
Total Cash (Recent Filing)HK$153.35M
Total Debt (Recent Filing)HK$24.83M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,401,358,800
10 Day Avg. Volume1,490,900
30 Day Avg. Volume3,709,666
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.88
Price to Sales (P/S)16.34
P/FCF Ratio-3.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Capital StructureLow debt and a sizable equity base give Rainmed financial flexibility to weather continued operational losses and delay urgent refinancing. Over a 2–6 month horizon this reduces insolvency risk and preserves optionality to fund restructuring, R&D, or targeted commercialization efforts without immediate liquidity stress.
Improving Cash Burn TrendA meaningful improvement in free cash flow in 2025 versus 2024 signals the company is narrowing its cash outflows. If sustained, this trend extends runway, lowers near-term financing need, and creates room to prioritize high-return investments or cost programs that support a durable move toward self-funded operations.
Medical-devices Industry ExposureOperating in the medical-devices sector means exposure to structurally durable healthcare demand and recurring procurement cycles. For a device maker, this end-market stability supports potential recovery and adoption of improved offerings, provided management can stabilize product economics and rebuild commercial traction over the medium term.
Bears Say
Sharp Revenue ContractionSteep multi-year revenue declines indicate lost market share or failing demand for current offerings, eroding scale and weakening operating leverage. Without revenue stabilization or new growth drivers, margin recovery and improved cash generation become much harder, prolonging dependence on external funding.
Negative Product EconomicsA negative gross margin shows costs exceed product pricing, reflecting unsustainable unit economics. Structural margin deficits force either margin-restoring actions or price increases; failing that, the company cannot achieve operating profitability, threatening long-term viability unless product costs or mix change materially.
Persistent Cash BurnContinuous negative operating and free cash flow necessitate ongoing external financing or equity issuance, increasing dilution and financing risk. Persistent cash burn constrains investment in commercialization or product development needed to reverse declines, raising the probability of balance-sheet pressure if losses persist.
Rainmed Medical Limited News
2297 FAQ
What was Rainmed Medical Limited’s price range in the past 12 months?
Rainmed Medical Limited lowest stock price was HK$0.19 and its highest was HK$0.53 in the past 12 months.
What is Rainmed Medical Limited’s market cap?
Rainmed Medical Limited’s market cap is HK$371.36M.
When is Rainmed Medical Limited’s upcoming earnings report date?
Rainmed Medical Limited’s upcoming earnings report date is Aug 27, 2026 which is in 74 days.
How were Rainmed Medical Limited’s earnings last quarter?
Rainmed Medical Limited released its earnings results on Mar 31, 2026. The company reported -HK$0.035 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.035.
Is Rainmed Medical Limited overvalued?
According to Wall Street analysts Rainmed Medical Limited’s price is currently Overvalued.
Does Rainmed Medical Limited pay dividends?
Rainmed Medical Limited does not currently pay dividends.
What is Rainmed Medical Limited’s EPS estimate?
Rainmed Medical Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rainmed Medical Limited have?
Rainmed Medical Limited has 1,401,358,800 shares outstanding.
What happened to Rainmed Medical Limited’s price movement after its last earnings report?
Rainmed Medical Limited reported an EPS of -HK$0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Rainmed Medical Limited?
Currently, no hedge funds are holding shares in HK:2297
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rainmed Medical Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.12%
12-Months-Change
Fundamentals
Return on Equity
-20.20%
Trailing 12-Months
Asset Growth
23.29%
Trailing 12-Months
Company Description
Rainmed Medical Limited
Rainmed Medical Limited is a medical technology firm specializing in the creation, development, and market launch of advanced systems that utilize coronary angiography to assess fractional flow reserve (FFR) and the index of microvascular resistance (IMR). Its offerings include the FlashAngio caFFR System, which accurately determines FFR values by reconstructing a three-dimensional model of the coronary arterial system from two angiographic images. Additionally, the company provides the FlashAngio caIMR System, an innovative non-invasive solution for the diagnosis and treatment of microcirculatory lesions. Rainmed Medical is also engaged in pioneering intelligent angiographic injection technologies, robotic navigation systems for vascular interventions, and flash renal denervation solutions. Established in 2014, the company is headquartered in Suzhou, China.
Technical Analysis
Acotec Scientific Holdings Limited
―
Vincent Medical Holdings Limited
―
Broncus Holding Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―